A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2
Study Overview
A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
- IRB Number: 11582
- Research Study Identifier: TX11414
- Principal Investigator: Utpal Dave, MD
Recruitment Status
Enrolling By InvitationIf you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.
